



BORDERLESS INNOVATION

Increasing Collaborations between Denmark and Japan in Biotech and Pharma

OCTOBER 9 2018

09:30 – 13:00

INVITATION TO BORDERLESS INNOVATION

- Date : October 9 2018 09:00 – 13:00
- Location : Daikanyama Hillside Terrace, Sarugakucho 18-8, Shibuya-ku, Tokyo ([LINK](#))
- Cost : Free of Charge
- Seats : 60 seats
- Contact: Royal Danish Embassy Mr. Takizawa TEL: 03-3780-8718 Email: petaki**um.dk)
- Language : Japanese and English (simultaneous translation)
- Registration : Please register here: [LINK](#) before October 1

Innovation is what drives the life science industry forward and in the global environment of today; working across borders is a necessity to stay competitive. Drivers and mechanisms of innovation is a complex subject without any easy answers. However, the interplay between governmental initiatives and industry activities play a key part.

Denmark and Japan consistently rank among the most innovative countries in the world within life science. What are the initiatives and policies in Denmark and Japan that are driving this and what type of support is offered to industry to encourage collaboration in biotech and pharmaceuticals between Denmark and Japan? This seminar will explore this and what opportunities there are for further collaborations between innovators in Denmark and Japan.

Program

*Speaker and Program are tentative and subject to change

TIME	TITLE	SPEAKER
09:00	Registration Open	
09:30	Welcome	H.E. Freddy Svane Ambassador of Denmark to Japan
09:35	Opening Words Importance of International Collaboration	TBD Japan BioIndustry Association
09:40	Danish Initiatives What Denmark does in furthering collaboration	Mr. Joakim Steen-Barron Mikkelsen Minister Councillor, Danish Embassy
10:00	Supporting bi-lateral Innovation Initiatives in Japan and perspectives on EU	Dr. Toshiyasu Ichioka Japan Science and Technology Agency
10:30	Open Innovation Sessions <ul style="list-style-type: none">• Leo Pharma A/S• Gubra ApS• Daiichi Sankyo Inc.• Lundbeck A/S• Immunitrack ApS• M Biotechnology K.K.	Company Representatives
11:45	Medicon Valley in the World	Mr. Niels Thun Andersen Copenhagen Capacity
11:55	Closing	TBD
12:00	Networking Lunch	
13:00		

Hosted by



Supported by



SPEAKERS



Name: Mr. Joakim Steen Barron-Mikkelsen

Affiliation: The Royal Danish Embassy

Mr. Joakim Steen Barron-Mikkelsen is Minister Counsellor – Economic Diplomacy in Health at the Royal Danish Embassy in Tokyo, Japan. Joakim has been appointed by the Danish minister for health as liaison officer in charge representing the Danish Ministry of Health in collaboration discussions with Japanese authorities. He has more than 15 years medical industry and public health experience, from both public and private sectors, promoting cooperation on innovative solutions with authorities, academia, clinical societies and

businesses. Previously, he was Regional Director – European Health of Government and Public Affairs with Otsuka Pharmaceuticals Ltd., and before that Denmark's US Health Care Attaché.

He has an economics background with speciality in technology and health management, following studies in Denmark, France and the USA. He holds a MSc. in Management of Technology from Copenhagen Business School.



Name: Dr. Toshiyasu Ichioka

Affiliation: Japan Science and Technology Agency

Toshiyasu Ichioka is Senior Strategist at the Department of International Affairs, Japan Science and Technology Agency (JST), working on the globalization of the entire organization, programmes, services and personnel. Prior to joining JST in May 2015, he was project manager at the EU-Japan Centre for Industrial Cooperation, heavily engaged in the promotion of Europe-Japan cooperation in innovation, science and technology through European Framework Programmes.

He has researcher background on experimental atomic physics and worked at various research organizations: Marie Curie Fellow at University of Latvia (LV), Max-Planck-Institute for Nuclear Physics (DE), Aarhus University (DK), CERN (CH) and RIKEN (JP). He holds a PhD and MSc in Multi-Disciplinary Sciences from University of Tokyo and a BSc in Physics from Kyoto University (JP).



Name: Mr. Niels Thun Andersen

Affiliation: Copenhagen Capacity

Niels is a business development manager at Copenhagen Capacity specialized in life science. Copenhagen Capacity is the official organisation for investment promotion and economic development in Greater Copenhagen. We support foreign companies, investors and talent in identifying and capitalising on business opportunities in Greater Copenhagen - from initial considerations to final establishment.

Niels is in charge of the life science sector and has more than 20 years of international experience from the pharmaceutical, medical devices and life science industry.

LEO PHARMA A/S



Speaker: Kazuhiko Takeshige, Ph.D. Director, Global Business Development

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company.

LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. To realise our vision of becoming the preferred dermatology care partner improving people's lives around the world, we are expanding into new regions and markets, reaching more patients and societies with drugs and therapies that address unmet medical needs.

LEO Pharma has its own sales forces in 61 countries and employs around 5,000 employees worldwide. The company is headquartered in Denmark and is wholly owned by the LEO Foundation.

GUBRA APS



Speaker: Mr. Henrik Blou, CEO

Founded in 2008, we are a privately-held biotech company with two primary areas of business: Pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs.

Our focus is the metabolic space (obesity, diabetes, NASH and gastrointestinal diseases), where we specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. Gubra is an abbreviation for GUT and BRAin, the original key focus areas of our research and expertise.

DAIICHI SANKYO CO.,LTD.



Speaker: Dr. Kohei Shimada, Director, Research Planning Group, Research Function

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.

Through the outstanding knowledge and commitment of our 15,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

Dr. Shimada is since 2017 the leader of the Open Innovation Leadership Team in Daiichi Sankyo. Dr. Shimada graduated from Tokyo University in 1990 and joined Sankyo in 1990. In addition to his work at Sankyo/Daiichi Sankyo, Dr. Shimada also was a Visiting Scientist at the

City of Hope National Medical Center (CA, USA) between 2001-2003.

LUNDBECK A/S



Speaker: Mr. Ryuji Deguchi, Consultant, Business Development

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at the disease areas depression, schizophrenia, Parkinson's disease and Alzheimer's disease.

Focus on R&D is the most important pillar in Lundbeck's ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have a state-of-the-art research facility in Denmark, and more than 800 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions.

IMMUNITRACK APS



Speaker: Dr. Robin Campbell, Board Director, Immunitrack

Predicting the patient immune response is a critical issue within the field of biotherapeutics. Immunitrack provides vaccine and biologics developers with in silico and in vitro tools and services for predicting the immune response to drug candidates.

Immunitrack's offering derives from our expertise in manufacturing and measuring the binding effectiveness of the major histocompatibility complexes (MHC) I and II. MHC I and II are essential for a patient's recognition of foreign molecules. Our unique immune response prediction platform combines in-house predictive bioinformatics software with highly sensitive MHC:peptide binding and stability assays. Our clients use this knowledge to select the most promising candidates for therapy and in order to move drug development forward. We also aid our customers in the redesign of drug/vaccine candidates that have predicted, or actual, undesired immunogenic effects.

Immunitrack works with more than 100 biotech companies worldwide, including 6 of the top 10 Pharma companies. Our company was founded in 2013 by Sune Justesen and Stephan Thorgrimsen. CSO Sune Justesen is a recognized expert in the field of MHC:peptide complex manufacture and assay development. The company started commercialization of its products and services in 2016, and has recently experienced rapid growth.

M BIO TECHNOLOGY INC.



Speaker: Dr. Kazuhiro Matsuda, CEO

M Bio Technology Inc. is the research-and-development type venture business established on January 5, 2005, and is specialized in the diagnosis, therapeutic and prevention of MID (Mycoplasma Infectious Diseases). MID is a major cause of pneumonia, asthma, COPD, fibrosis, and further, allergic and autoimmune diseases. MID is also a cause of mental and

neurological disorders.

M Bio Technology Inc. is challenging to establish an innovative diagnostics, precision preventive medicine, and vaccines. The diagnostics and drug design to the pathogenic microorganisms using the synthesized glycolipid-antigens are world's first platform technology.



We would like to introduce our evolutionally innovative asset/product/services, which are solutions to solve the problems of public health and healthy industry and ecosystem, then lead us to promising new era of medicine. We are seeking for partnering opportunities to create global medical network for MID.